Abstract
BackgroundThe clinical significance of tumor-specific genomic alterations in metastatic renal cell carcinoma (mRCC) is emerging, with several studies suggesting an association between PBRM1 mutations and response with immunotherapy (IO). We...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have